{"id":"4273588a-06a0-56ea-8dba-96a4f5bccbb9","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-mouse-acadm","predicate":"increases_in_recorded_comparison","statement":"Apigenin increased hepatic ACADM mRNA in the high-fat-fed mouse experiment.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"9fa6cfad-6ca7-553d-b71d-54f955979205","mechanism_event_label":"Apigenin increased hepatic ACADM mRNA in the high-fat-fed mouse experiment.","subject":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"object":{"id":"5ff11d66-6593-5fd5-b2a9-1b6d24205032","slug":"mouse-acadm","display_name":"Mouse medium-chain acyl-CoA dehydrogenase / Acadm","entity_type_key":"protein"},"evidence_count":1,"mechanism_event":{"id":"9fa6cfad-6ca7-553d-b71d-54f955979205","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-mouse-acadm-event","event_type":"experimental_observation","label":"Apigenin increased hepatic ACADM mRNA in the high-fat-fed mouse experiment.","description":"### api-mouse-acadm\n\nApigenin increased hepatic ACADM mRNA in the high-fat-fed mouse experiment.\nTranscript abundance is not enzyme activity or measured fatty-acid oxidation flux.\nModel and exposure: 100 mg/kg intraperitoneally daily, 7 days.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. | 2013 | https://pubmed.ncbi.nlm.nih.gov/23172919/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC3609577/ | https://doi.org/10.2337/db12-1139 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"Apigenin","sequence_order":0,"notes":""},{"entity":{"id":"5ff11d66-6593-5fd5-b2a9-1b6d24205032","slug":"mouse-acadm","display_name":"Mouse medium-chain acyl-CoA dehydrogenase / Acadm","entity_type_key":"protein"},"role":"measured outcome","stoichiometry":null,"state_label":"increase","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Apigenin\", \"comparator\": \"Vehicle\", \"endpoint\": \"Apigenin increased hepatic ACADM mRNA in the high-fat-fed mouse experiment.\", \"effect_direction\": \"increase\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"100 mg/kg intraperitoneally daily, 7 days.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Apigenin collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Apigenin increased hepatic ACADM mRNA in the high-fat-fed mouse experiment.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. | https://pubmed.ncbi.nlm.nih.gov/23172919/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC3609577/ | https://doi.org/10.2337/db12-1139","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference api-mouse-acadm; Transcript abundance is not enzyme activity or measured fatty-acid oxidation flux.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"052f2b30-0514-5e26-99ff-1b6b4af1321d","evidence_kind":"source_excerpt","locator":"Lines 256-262","start_line":256,"end_line":262,"excerpt":"### api-mouse-acadm\n\nApigenin increased hepatic ACADM mRNA in the high-fat-fed mouse experiment.\nTranscript abundance is not enzyme activity or measured fatty-acid oxidation flux.\nModel and exposure: 100 mg/kg intraperitoneally daily, 7 days.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. | 2013 | https://pubmed.ncbi.nlm.nih.gov/23172919/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC3609577/ | https://doi.org/10.2337/db12-1139 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","model_system":"100 mg/kg intraperitoneally daily, 7 days.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"54eac90b-add1-5f56-9036-d900307c5697","stable_key":"import-ff370329-68a3-573d-96ee-597de78a3967","title":"Apigenin: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"ede6e5c6b91d66b66844f2ff667a7f8303d9ac1281f15dc09db703f7de4da942","revision_id":"b41a39a2-0197-549c-97a5-1765e6696931","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}